Amgen wants Sandoz to give up info on regulatory approval for generic Prolia, Xgeva
Intellectual Property 2025-05-05 11:22 pm By Christine Caulfield
Please login to bookmark Close

Biopharmaceutical company Amgen has lodged proceedings against generic maker Sandoz, calling for documents related to regulatory approval of a generic version of its top-selling bone disease treatments.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au